Humanigen Inc (OTCMKTS:HGEN) said Friday that the editors of the medical journal blood featured on the cover of the current edition, a study of the use of the company's proprietary monoclonal antibody.
The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells. The study involving lenzilumab showed a reduction in cytokine release syndrome and neuroinflammation as well as an enhancement in CAR-T cell function, according to the Burlingame, California, company.
The study, conducted with lab mice, was designed to replicate the effects seen in CAR-T clinical trials. It used human acute lymphoblastic leukemia cells, human CD19 targeted CAR-T (CART19) cells and human peripheral blood mononuclear cells.
The use of lenzilumab with CART19 therapy resulted in significant improvement in leukemic disease control, sustained for at least 35 days after CART19 administration, compared with a control, according to Humanigen.
“This work represents a significant advance in understanding how to improve efficacy and safety of CAR-T,” Dr Cameron Durrant, CEO of Humanigen, said in a statement.
Shares of the company rose 1.1% to $0.93 in Thursday’s OTC Markets trading.
Contact Dennis Fitzgerald at [email protected]